Abaloparatide
Also referenced as: Tymlos
A PTH-related-peptide analogue used for high-risk osteoporosis.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Tymlos is FDA-approved for specified high-fracture-risk postmenopausal osteoporosis and bone-density improvement in men with high-risk osteoporosis, including treatment-failure or intolerance criteria.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A PTH-related-peptide analogue used for high-risk osteoporosis.
Tymlos is FDA-approved for specified high-fracture-risk postmenopausal osteoporosis and bone-density improvement in men with high-risk osteoporosis, including treatment-failure or intolerance criteria.
Bone-building effects are not evidence for athletic enhancement or general connective-tissue repair.
Why It's Being Studied
- High-risk osteoporosis
- Bone formation
Mechanism of Action
PTH1-receptor activation promotes bone formation in the studied treatment context.
PTH1-receptor activation promotes bone formation in the studied treatment context. Bone-building effects are not evidence for athletic enhancement or general connective-tissue repair.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- High-risk osteoporosis
- Bone formation
- Subcutaneous approved medicine
Evidence Summary
Randomized human studies support fracture-risk and bone-density outcomes in specifically labeled osteoporosis populations.
Higher tiers carry more weight. Filled tiers have evidence for Abaloparatide; tap to read it.
- Randomized human studies support fracture-risk and bone-density outcomes in specifically labeled osteoporosis populations.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Randomized human studies support fracture-risk and bone-density outcomes in specifically labeled osteoporosis populations.
Reported Adverse Events in Research
- Hypercalcemia or hypercalciuria, orthostatic symptoms and osteosarcoma-risk precautions require attention.
Limitations of Current Evidence
- Bone-building effects are not evidence for athletic enhancement or general connective-tissue repair.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Abaloparatide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Abaloparatide — prescribing label